Clinical trials: Acute Infectious Diseases
COVID-19
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
Study of ANA001 in Moderate and Severe COVID-19 Patients
- Trial name
- NCT04603924
- Testing
- Niclosamide
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Skin Infections, Bacterial
GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection
This study will determine the safety, tolerability and efficacy of GSK1322322 verses Linezolid in subjects with Acute Bacterial Skin and Skin Structure Infection (ABSSSI).
- Trial name
- NCT01209078
- Testing
- GSK1322322, Linezolid
- Where
- 7 sites in United States
- Volunteers
- 84 people
- Sponsor
- GlaxoSmithKline
Tracheitis, Tracheobronchitis
Evaluation of the Treatment With Klacid®SR in Patients With Lower Respiratory Tract Infection
The aim of this post-marketing observational study (PMOS) is to describe the relief of symptoms, tolerability and compliance of treatment with Klacid®SR in a dose 1000 mg once daily in patients with lower respiratory tract…
- Conditions
- Tracheitis, Tracheobronchitis, Bronchitis, Chronic Bronchitis
- Trial name
- NCT01108185
- Where
- 158 sites in Slovakia
- Volunteers
- 3,181 people
- Sponsor
- Abbott
Urinary Tract Infections
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
This is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regimen to be used in the…
- Trial name
- ELIMINATE (NCT05488340)
- Testing
- LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose
- Where
- 17 sites in United States
- Volunteers
- 318 people
- Sponsor
- Locus Biosciences
Hepatitis C, Human Immunodeficiency Virus
Treatment of Acute Hepatitis C Virus in HIV Co-Infection
This study is designed to test the hypothesis that treatment of hepatitis C virus (HCV) infection during the first 6 months after acquiring HCV among people who already have pre-existing HIV infection will result in improved…
- Conditions
- Hepatitis C, Human Immunodeficiency Virus, HIV Infections
- Trial name
- NCT00845676
- Testing
- Pegylated interferon alfa-2a + Ribavirin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco
Acute Liver Failure, Acute Liver Injury
Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury
This Phase 2a clinical study is designed to provide data on OCR-002 in patients with acute liver failure/acute liver injury (ALF/ALI) in regard to: safety and tolerability; metabolism of the compound to glutamine and…
- Trial name
- STOP-ALF (NCT01548690)
- Testing
- Ornithine Phenylacetate
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- William Lee
Covid19, Stress, Psychological
Psychological Impact of COVID-19 Pandemic in Healthcare Workers
Background. The current coronavirus disease (COVID-19) has a great impact worldwide. Healthcare workers play an essential role and are one of the most exposed groups.Information about the psychosocial impact on healthcare workers…
- Conditions
- Covid19, Stress, Psychological, Work Related Stress, Epidemic Disease
- Trial name
- PSIMCOV (NCT04506515)
- Testing
- Psychological stress and adaptation at work score (PSAS)
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Hospital General Universitario de Valencia
Hepatitis C, Acute Hepatitis C
Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir
This is a single arm multicenter pilot study to evaluate the efficacy and safety of treatment with sofosbuvir (SOF)/velpatasvir (VEL) fix dose combination (FDC) in patients with acute hepatitis C virus (HCV) infection.
- Trial name
- NCT03818308
- Testing
- Sofosbuvir and Velpatasvir
- Where
- 14 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Hannover Medical School
Osteoarthritis, Rheumatoid Arthritis
A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2
Randomized, Open-label, Oral, Single-dose, two-Sequence, four-Period, crossover study
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Back Pain, Acute Upper Respiratory Tract Infection
- Trial name
- NCT05214690
- Testing
- DW1809-T2, DW1809-1
- Where
- South Korea
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Respiratory Infections, Bronchiolitis
An Epidemiological Study to Evaluate the RSV-Associated Lower Respiratory Track in Infections in Infants
The primary objective of this study is to describe the incidence of RSV-associated LRI among infants <1 year of age presenting to the ED during selected shoulder months.
- Conditions
- Respiratory Infections, Bronchiolitis, Pneumonia, Apnea
- Trial name
- NCT00369759
- Testing
- Emergency Dept. Subjects with LRI or Apnea
- Where
- 38 sites in United States
- Volunteers
- 2,048 people
- Sponsor
- MedImmune LLC
Covid19, Sars-CoV-2 Infection
Post Acute Sequelae of COVID-19
COVID-19, a novel coronavirus, has caused widespread mortality and morbidity since it emerged in 2019. There is ongoing research and growing literature describing severe acute respiratory syndrome (SARS-COV-2).
- Conditions
- Covid19, Sars-CoV-2 Infection, Dyspnea Caused by 2019-nCoV, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- PASC (NCT04964115)
- Testing
- Cohort study
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Vanderbilt University Medical Center
Covid19, SARS-CoV Infection
Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19
This is a single center, randomized, double-blind, 2-arm, parallel-group study of DuACT in participants with clinical symptoms of COVID-19 that have begun within the past 72 hours prior to testing.
- Trial name
- DuACT (NCT04563208)
- Testing
- DuACT
- Where
- South Africa
- Volunteers
- 80 people
- Sponsor
- University of Witwatersrand, South Africa
Covid19, SARS-CoV-2 Infection
Montelukast - a Treatment Choice for COVID-19
The current study aimed to make a therapeutic comparison and effectiveness of Hydroxychloroquine (HCQ) and Montelukast (ML) in COVID-19 patients in addition to the standard of care.
- Trial name
- NCT04714515
- Testing
- Montelukast, Hydroxychloroquine, Ivermectin
- Where
- 2 sites in China, Pakistan
- Volunteers
- 150 people
- Sponsor
- University of Sargodha
Post-COVID-19 Syndrome
Balneotherapy for Patients With Post-acute Coronavirus Disease (COVID) Syndrome
The goal of this randomized controlled study is to evaluate the effects of balneotherapy (BT) and aquatic exercises in patients with post-acute COVID syndrome (PACS).
- Trial name
- NCT05765591
- Testing
- Balneotherapy and aquatic exercises
- Where
- Spain
- Volunteers
- 98 people
- Sponsor
- Parc de Salut Mar
COVID, Sars-CoV2
Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement
Prospective registry for multimodal assessment of neuromuscular pathology associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, enrolling consecutive patients with corona virus disease 2019…
- Conditions
- COVID, Sars-CoV2, Corona Virus Infection, Myositis
- Trial name
- NCT04367350
- Testing
- laboratory biomarkers, muscle ultrasound
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University Hospital Tuebingen
Infection, Lung Parenchyma
Inventory of the Management of Acute Community-acquired Pneumonia in Strasbourg University Hospitals
Acute community-acquired pneumonia (CAP) refers to an acute infection of the lung parenchyma, occurring within the first 48 hours of hospitalization. It is a frequent, serious pathology with a strong economic impact.
- Trial name
- PPAC (NCT05661513)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Strasbourg, France
Human Immunodeficiency Virus
Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults
This is a Phase I, randomized, double-blind, placebo-controlled clinical study to define the safety and immunogenicity resulting from a rapid dose-escalating vaccination schedule as compared to that of a co-administered…
- Trial name
- RV591 (NCT06205056)
- Testing
- Ad26.Mos4.HIV in CH505 TF chTrimer + ALFQ [Arm 1a], CH505 TF chTrimer + ALFQ [Arm 1a], Ad26.Mos4.HIV in CH505 TF chTrimer +ALFQ [Arm 2a]
- Where
- Uganda
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Acute Uncomplicated Bacterial Cystitis
Epidemiology of Acute Bacterial Uncomplicated Cystitis in General Practice
Acute uncomplicated bacterial cystitis is common in general practice. Cystitis is at the second raw of antibiotic treatment indications.
- Trial name
- BaCyst (NCT00958295)
- Where
- France
- Volunteers
- 362 people
- Sponsor
- University Hospital, Rouen
Abscess, Wound Infection
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a…
- Conditions
- Abscess, Wound Infection, Surgical Site Infection, Cellulitis
- Trial name
- NCT01431339
- Testing
- IV Dalbavancin, Vancomycin/Linezolid
- Where
- 137 sites in United States, Bulgaria and 12 more
- Volunteers
- 739 people
- Sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc
Sars-CoV-2 Infection
Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention
The investigated product is a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Booster Vaccine candidate optimized for the Omicron/BA.2 variant.
- Trial name
- NCT05844202
- Testing
- Alveavax-v1.2, Janssen Ad26.COV2.S
- Where
- 8 sites in South Africa
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Alvea Holdings, LLC